Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2024-04-12 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
2023年度募集资金存放与使用情况专项鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2023年度募集资金存放与使用情况专项鉴证报告" which translates to "2023 Annual Fundraising Funds Deposit and Usage Special Verification Report". It is issued by Shenzhen BGI Genomics Co., Ltd. and includes detailed information about the company's fundraising activities, the management and use of raised funds, and verification by an accounting firm (Ernst & Young Hua Ming). The document references regulatory guidelines related to fundraising management and usage, and provides detailed tables and explanations about the use of funds raised through a specific share issuance. The document is a standalone audit/verification report focused on the use and management of fundraising proceeds, not a full annual report or earnings release. It is not a simple announcement or a certification letter but a substantive verification report. Therefore, it fits the category of an Audit Report / Information (AR). FY 2023
2024-04-12 Chinese
关于2023年度利润分配预案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the 2023 annual profit distribution plan of Shenzhen BGI Genomics Co., Ltd. It details the proposed dividend payout, legal compliance, and approvals from the board of directors, independent directors, and supervisory board. The document does not contain full financial statements or comprehensive financial performance data but focuses on the dividend distribution proposal and related approvals. The document length is 2636 characters, which is relatively short and primarily serves as a formal announcement of the dividend plan rather than a full report. Therefore, it fits the category of Notice of Dividend Amount (DIV), which covers announcements of dividend amounts, payment dates, and details for shareholders.
2024-04-12 Chinese
2023年年度报告
Annual Report Classification · 100% confidence The document is titled "2023 年年度报告" which translates to "2023 Annual Report". It contains detailed financial data such as revenue, net profit, cash flow, and other financial indicators for the fiscal year 2023. The text includes sections like "管理层讨论与分析" (Management Discussion and Analysis), company information, accounting firm details, and audit report references. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The presence of comprehensive financial statements and management analysis confirms this is the official yearly report covering company activity and full financial performance, matching the definition of an Annual Report (10-K). FY 2023
2024-04-12 Chinese
关于2024年度为子公司提供担保额度预计的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Shenzhen BGI Genomics Co., Ltd. regarding the estimated guarantee amount to be provided to its subsidiaries for the year 2024. It details the board and supervisory committee meetings held to approve the guarantee, the guarantee amount, the financial status of the subsidiaries, and the rationale and risk assessment for the guarantees. The document is a formal disclosure of a corporate action related to providing financial guarantees to subsidiaries, including meeting resolutions and financial data of the subsidiaries. It is not a financial report, earnings release, or management discussion, nor is it a regulatory certification or a report publication announcement. The content fits best under a regulatory announcement category related to financing activities, specifically about guarantees and credit facilities, which aligns with Capital/Financing Update (CAP). The document is about the company's financing support to subsidiaries and the related board approvals, which is typical for CAP filings.
2024-04-12 Chinese
董事会对独董独立性评估的专项意见
Board/Management Information Classification · 95% confidence The document is a special opinion from the board of directors regarding the independence of the company's independent directors for the year 2023. It references regulatory guidelines and the company's articles of association, and it assesses the independence of specific directors. The content is focused on governance and compliance with independence requirements for board members, rather than financial results, audit opinions, or shareholder voting outcomes. It does not contain financial data or results, nor is it an announcement of a report publication. This fits best under Board/Management Information (MANG), which covers announcements related to board members and management, including their status and compliance.
2024-04-12 Chinese
2023年度非经营性资金占用及其他关联资金往来情况的专项说明
Audit Report / Information Classification · 95% confidence The document is a detailed special explanation regarding non-operating fund occupation and other related party fund transactions for the year 2023 by Shenzhen BGI Genomics Co., Ltd. It includes audited financial data and tables summarizing related party transactions and balances as of December 31, 2023. The document references an audit report issued by Ernst & Young Hua Ming dated April 11, 2024, and states that the data should be read together with the audited financial statements. The content is focused on financial data and audit verification related to specific financial transactions and balances, not a full annual report or earnings release. It is a standalone audit-related report providing detailed information on related party transactions and fund usage, consistent with an Audit Report / Information filing rather than a full Annual Report or other categories. The document length (8321 characters) and detailed financial tables support this classification. Therefore, the document is best classified as an Audit Report / Information (AR). FY 2023
2024-04-12 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.